pefcalcitol (M 518101) / Maruho - LARVOL DELTA

New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults. (PubMed, Expert Opin Pharmacother) - "Cost is also a barrier for many patients. Recent development of new synthetic treatment options is promising, and we recommend that providers consider these agents as they develop holistic and individualized treatment plans for their patients."

Journal • Dermatology • Immunology • Psoriasis

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Maruho Co., Ltd. | N=50 ➔ 0 | Unknown status ➔ Withdrawn

Enrollment change • Trial withdrawal • Dermatology • Immunology • Psoriasis

Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers (clinicaltrials.gov) - P1; N=240; Completed; Sponsor: Maruho North America Inc.; Active, not recruiting ➔ Completed; N=200 ➔ 240

Enrollment change • Trial completion • Biosimilar